DRKS00032764招募中Unknown
Building a nationwide safety net for oral antitumor therapy: SafetyFIRST – a cluster-randomized stepped-wedge trial - SafetyFIRST
Apotheke des Uniklinikums Erlangen0 个研究点目标入组 600 人开始时间: 2023年11月16日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Therapy initiation at one of the participating local sites with:
- •- A newer oral anti-tumor agent (substance authorized for use after February 2, 2001 = date of authorization for Capecitabine by the European Medicines Agency EMA), or
- •- Temozolomide (inclusion due to high clinical relevance despite approval before the approval date for Capecitabine).
- •- Planned duration of therapy: at least 4 months
- •- Estimated life expectancy: at least 4 months
- •- Ability to independently fill out questionnaires
- •- Tumor diagnosis / stages: no limitations
- •- Treatment setting: outpatient (or inpatient) treatment setting, outpatient follow-up care
排除标准
- •- Absence of sufficient German language skills (ability to understand written and spoken German)
- •- Pathological cognitive deficiencies (e.g., neurodegenerative diseases severely affecting patients' memory)
- •- Non-capable-of-consent patients
- •- Patients unable to take their medication independently
- •- Pregnant / breastfeeding patients
- •- Absence of written consent statement
研究者
相似试验
已完成
不适用
Development of a preventive oral health programme for Multiple Sclerosis (MS) patientsMultiple sclerosis and oral healthOral HealthISRCTN87621500HS R&D Regional Programme Register - Department of Health (UK)
进行中（未招募）
1 期
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatmentcMET-dependent malignanciesMedDRA version: 19.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005144-42-ESovartis Farmacéutica, S.A.60
进行中（未招募）
1 期
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatmentcMET-dependent malignanciesMedDRA version: 20.0 Level: LLT Classification code 10048683 Term: Advanced cancer System Organ Class: 100000004864EUCTR2016-005144-42-DKovartis Pharma AG60
进行中（未招募）
1 期
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatmentcMET-dependent malignanciesMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-005144-42-SEovartis Pharma AG60
进行中（未招募）
1 期
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatmentcMET-dependent malignanciesMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-005144-42-ATovartis Pharma AG60